vs

Side-by-side financial comparison of Organogenesis Holdings Inc. (ORGO) and STONERIDGE INC (SRI). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $205.2M, roughly 1.1× STONERIDGE INC). On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs -6.0%). Organogenesis Holdings Inc. produced more free cash flow last quarter ($34.8M vs $2.6M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs -7.4%).

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.

ORGO vs SRI — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.1× larger
ORGO
$225.6M
$205.2M
SRI
Growing faster (revenue YoY)
ORGO
ORGO
+84.1% gap
ORGO
78.1%
-6.0%
SRI
More free cash flow
ORGO
ORGO
$32.1M more FCF
ORGO
$34.8M
$2.6M
SRI
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
-7.4%
SRI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ORGO
ORGO
SRI
SRI
Revenue
$225.6M
$205.2M
Net Profit
$43.7M
Gross Margin
16.2%
Operating Margin
28.1%
-14.4%
Net Margin
19.4%
Revenue YoY
78.1%
-6.0%
Net Profit YoY
469.5%
EPS (diluted)
$0.31
$-2.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORGO
ORGO
SRI
SRI
Q4 25
$225.6M
$205.2M
Q3 25
$150.9M
$210.3M
Q2 25
$101.0M
$228.0M
Q1 25
$86.7M
$217.9M
Q4 24
$126.7M
$218.2M
Q3 24
$115.2M
$213.8M
Q2 24
$130.2M
$237.1M
Q1 24
$110.0M
$239.2M
Net Profit
ORGO
ORGO
SRI
SRI
Q4 25
$43.7M
Q3 25
$21.6M
$-9.4M
Q2 25
$-9.4M
$-9.4M
Q1 25
$-18.8M
$-7.2M
Q4 24
$7.7M
Q3 24
$12.3M
$-7.1M
Q2 24
$-17.0M
$2.8M
Q1 24
$-2.1M
$-6.1M
Gross Margin
ORGO
ORGO
SRI
SRI
Q4 25
16.2%
Q3 25
20.3%
Q2 25
21.5%
Q1 25
72.6%
21.2%
Q4 24
75.5%
19.5%
Q3 24
76.7%
20.8%
Q2 24
77.6%
22.7%
Q1 24
73.9%
20.2%
Operating Margin
ORGO
ORGO
SRI
SRI
Q4 25
28.1%
-14.4%
Q3 25
13.7%
-1.6%
Q2 25
-12.5%
-1.1%
Q1 25
-30.9%
-1.5%
Q4 24
8.1%
-2.0%
Q3 24
5.4%
0.1%
Q2 24
-10.7%
1.4%
Q1 24
-3.5%
0.1%
Net Margin
ORGO
ORGO
SRI
SRI
Q4 25
19.4%
Q3 25
14.3%
-4.5%
Q2 25
-9.3%
-4.1%
Q1 25
-21.7%
-3.3%
Q4 24
6.1%
Q3 24
10.7%
-3.3%
Q2 24
-13.1%
1.2%
Q1 24
-1.9%
-2.6%
EPS (diluted)
ORGO
ORGO
SRI
SRI
Q4 25
$0.31
$-2.76
Q3 25
$0.11
$-0.34
Q2 25
$-0.10
$-0.34
Q1 25
$-0.17
$-0.26
Q4 24
$0.05
$-0.22
Q3 24
$0.09
$-0.26
Q2 24
$-0.13
$0.10
Q1 24
$-0.02
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORGO
ORGO
SRI
SRI
Cash + ST InvestmentsLiquidity on hand
$93.7M
$66.3M
Total DebtLower is stronger
$180.9M
Stockholders' EquityBook value
$300.1M
$179.8M
Total Assets
$598.7M
$551.2M
Debt / EquityLower = less leverage
1.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORGO
ORGO
SRI
SRI
Q4 25
$93.7M
$66.3M
Q3 25
$63.7M
$54.0M
Q2 25
$73.1M
$49.8M
Q1 25
$110.0M
$79.1M
Q4 24
$135.6M
$71.8M
Q3 24
$94.3M
$54.1M
Q2 24
$89.9M
$42.1M
Q1 24
$88.6M
$48.4M
Total Debt
ORGO
ORGO
SRI
SRI
Q4 25
$180.9M
Q3 25
Q2 25
Q1 25
Q4 24
$201.6M
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
ORGO
ORGO
SRI
SRI
Q4 25
$300.1M
$179.8M
Q3 25
$255.1M
$251.2M
Q2 25
$233.2M
$260.5M
Q1 25
$242.9M
$253.1M
Q4 24
$262.9M
$245.3M
Q3 24
$278.5M
$271.4M
Q2 24
$263.5M
$270.5M
Q1 24
$278.0M
$277.3M
Total Assets
ORGO
ORGO
SRI
SRI
Q4 25
$598.7M
$551.2M
Q3 25
$509.8M
$632.1M
Q2 25
$461.1M
$639.4M
Q1 25
$467.4M
$657.4M
Q4 24
$497.9M
$621.6M
Q3 24
$446.3M
$662.5M
Q2 24
$443.2M
$666.7M
Q1 24
$458.5M
$675.4M
Debt / Equity
ORGO
ORGO
SRI
SRI
Q4 25
1.01×
Q3 25
Q2 25
Q1 25
Q4 24
0.82×
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORGO
ORGO
SRI
SRI
Operating Cash FlowLast quarter
$39.4M
$8.8M
Free Cash FlowOCF − Capex
$34.8M
$2.6M
FCF MarginFCF / Revenue
15.4%
1.3%
Capex IntensityCapex / Revenue
2.1%
3.0%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M
$12.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORGO
ORGO
SRI
SRI
Q4 25
$39.4M
$8.8M
Q3 25
$3.1M
$3.6M
Q2 25
$-32.9M
$10.7M
Q1 25
$-19.9M
$10.9M
Q4 24
$10.9M
$19.2M
Q3 24
$8.7M
$10.8M
Q2 24
$4.7M
$8.7M
Q1 24
$-10.2M
$9.1M
Free Cash Flow
ORGO
ORGO
SRI
SRI
Q4 25
$34.8M
$2.6M
Q3 25
$844.0K
$-2.7M
Q2 25
$-36.5M
$7.4M
Q1 25
$-23.6M
$4.8M
Q4 24
$7.6M
$14.0M
Q3 24
$6.1M
$4.6M
Q2 24
$2.9M
$1.5M
Q1 24
$-12.4M
$3.3M
FCF Margin
ORGO
ORGO
SRI
SRI
Q4 25
15.4%
1.3%
Q3 25
0.6%
-1.3%
Q2 25
-36.1%
3.3%
Q1 25
-27.2%
2.2%
Q4 24
6.0%
6.4%
Q3 24
5.3%
2.2%
Q2 24
2.2%
0.6%
Q1 24
-11.3%
1.4%
Capex Intensity
ORGO
ORGO
SRI
SRI
Q4 25
2.1%
3.0%
Q3 25
1.5%
3.0%
Q2 25
3.6%
1.4%
Q1 25
4.2%
2.8%
Q4 24
2.7%
2.4%
Q3 24
2.2%
2.9%
Q2 24
1.4%
3.0%
Q1 24
2.0%
2.4%
Cash Conversion
ORGO
ORGO
SRI
SRI
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
3.11×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ORGO
ORGO

Segment breakdown not available.

SRI
SRI

Control Devices$51.7M25%
Electronics$38.0M19%
EE$34.2M17%
SE$28.6M14%
NL$24.5M12%
Stoneridge Brazil$14.1M7%
Asia Pacific$13.1M6%

Related Comparisons